Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Morgan Stanley Reiterates Overweight on Viking Therapeutics, Maintains $105 Price Target

Author: Benzinga Newsdesk | September 12, 2024 08:11am

Morgan Stanley analyst Michael Ulz reiterates Viking Therapeutics (NASDAQ:VKTX) with a Overweight and maintains $105 price target.

Posted In: VKTX